| 000 | 01881 a2200589 4500 | ||
|---|---|---|---|
| 005 | 20250517105023.0 | ||
| 264 | 0 | _c20180209 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1095-953X | ||
| 024 | 7 |
_a10.1016/j.nbd.2016.07.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRuneberg-Roos, Pia | |
| 245 | 0 | 0 |
_aDeveloping therapeutically more efficient Neurturin variants for treatment of Parkinson's disease. _h[electronic resource] |
| 260 |
_bNeurobiology of disease _cDec 2016 |
||
| 300 |
_a335-345 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAmphetamine _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCHO Cells |
| 650 | 0 | 4 | _aCricetulus |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aGenetic Variation _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMacaca fascicularis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 |
_aNeurturin _xchemistry |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-ret _xgenetics |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aStereotyped Behavior _xdrug effects |
| 650 | 0 | 4 |
_aSympatholytics _xtoxicity |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aPiccinini, Elisa | |
| 700 | 1 | _aPenttinen, Anna-Maija | |
| 700 | 1 | _aMätlik, Kert | |
| 700 | 1 | _aHeikkinen, Hanna | |
| 700 | 1 | _aKuure, Satu | |
| 700 | 1 | _aBespalov, Maxim M | |
| 700 | 1 | _aPeränen, Johan | |
| 700 | 1 | _aGarea-Rodríguez, Enrique | |
| 700 | 1 | _aFuchs, Eberhard | |
| 700 | 1 | _aAiravaara, Mikko | |
| 700 | 1 | _aKalkkinen, Nisse | |
| 700 | 1 | _aPenn, Richard | |
| 700 | 1 | _aSaarma, Mart | |
| 773 | 0 |
_tNeurobiology of disease _gvol. 96 _gp. 335-345 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.nbd.2016.07.008 _zAvailable from publisher's website |
| 999 |
_c26235691 _d26235691 |
||